A-
Overall grade
B+
Financial quality
The sleeper story is demand acceleration - new patient starts doubled records while requiring expensive whole exome sequencing that management is celebrating despite margin pressure. The obvious revenue beat masks the real story of operating leverage finally kicking in, with $80M guide raise while holding OpEx flat. The binding constraint is no longer capital or capacity - it's commercial execution on coverage wins for the $250-300M non-covered tumor opportunity. Chapman's most revealing quote: 'We ran so many exomes for first-time patients, which, of course, is very good news' - they're willing to sacrifice short-term margins for long-term patient acquisition. My view changes if new patient adds revert to normal levels next quarter, suggesting Q2 was a one-time surge rather than sustainable acceleration.
The 30-second version
- First-time patient starts doubled previous record, creating a COGS spike that management is celebrating
- Guidance raise of $80M revenue but held OpEx flat signals they've cracked the operating leverage code
- AI foundation models quietly launched as potential pharma partnership goldmine, but no monetization timeline
What changed this quarter
| Metric | Prior | This quarter |
|---|---|---|
| Revenue | $502M (+37% YoY) | $547M (+32% YoY) |
| Signatera Clinical Units | 16.5K sequential adds (record) | 20K sequential adds (new record) |
| Signatera ASP | $1,100+ | $1,175 |
| Gross Margin | 63% (60.4% ex true-ups) | 63.4% (steady ex true-ups) |
| New Patient Starts | Strong quarter (no number) | Double previous record |
| DSO | Not disclosed Q1 | 57 days |
| Oncology Volume | Record volume quarter | 189K tests |
| Revenue True-ups | $34M | $45M |
Accountability tracked
8 new promises made5 narrative shifts flagged6 prior promises graded
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Subscribe to Call Sheet Daily →